Ascaridida infectious disease

Summary

Ascaridida infectious disease (MONDO:0005656) is a disease (an umbrella term covering 6 Mondo subtypes). A subtype of Rhabditida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Ascaridida infectious disease
Mondo ID	MONDO:0005656
MeSH	D017191
GARD	0027726
Is cancer (heuristic)	no

Also known as: Ascaridida caused disease or disorder · Ascaridida disease or disorder · Ascaridida infection · infection, Ascaridida · infections, Ascaridida

Disease family

This is a subtype of Rhabditida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › Ascaridida infectious disease

Related subtypes (11): thelaziasis, ancylostomiasis, enterobiasis, mansonelliasis, oesophagostomiasis, setariasis, strongyloidiasis, trichostrongylosis, dirofilariasis, dracunculiasis, onchocerciasis

Subtypes (6): baylisascariasis, ascariasis, ascaridiasis, toxascariasis, toxocariasis, anisakiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.